PDF
(Download)
|
- Coffee (Coffea arabica)
- Breast Cancer
- Hormone- and Non-hormone-responsive Tumors
| Date:
10-14-2011 | HC#
061136-434
|
Re:
Coffee Consumption Lowers Risk for Non-hormone-responsive Breast Cancer Subtypes
Li
J, Seibold P, Chang-Claude J, et al. Coffee consumption modifies risk of
estrogen-receptor negative breast cancer. Breast
Cancer Res. 2011;13(3):R49. doi: 10.1186/bcr2879.
Breast
cancer can be divided into hormone-responsive (estrogen receptor [ER]-positive)
and non-hormone-responsive (ER-negative) subtypes. Some reports suggest that
heterogeneity exists in the associations between coffee (Coffea arabica) consumption and breast cancer risk, according to
the two subtypes. The authors assessed the association between coffee consumption
and postmenopausal breast cancer risk in a large population-based study overall
and stratified by ER tumor subtypes.
Coffee,
a complex mixture of caffeine and polyphenols, has been shown in experimental
studies to alter cancer risk. Experimental and clinical studies have suggested
that it can play a dual role as both a carcinogen, in which it inhibits
cellular repair of DNA or enhances cell proliferation, and a chemopreventive
agent with antioxidative and estrogenic properties. Most studies suggest that
high coffee consumption is associated with a modest reduction of breast cancer
risk.
Subjects
were drawn from a population-based case-control study described previously.1
The parent study included women aged 50 to 74 years born in Sweden and living
there between October 1, 1993 and March 31, 1995. The authors attempted to
contact all incident cases of invasive breast cancer in this study group.
Included in their study were 2,818 women with breast cancer and 3,111 controls.
For
the validation analysis, data were collected from the Mamma Carcinoma Risk
Factor Investigation (MARIE),2 carried out from August 2002 to
September 2005 in two study regions in Germany. It included 3,464
postmenopausal women aged 50 to 74 years with primary invasive or in situ breast
tumors and 6,657 controls.
The
authors collected data by means of an extensive mailed questionnaire requesting
detailed information on established and possible breast cancer risk factors,
including reproductive and menstrual history, family history of breast cancer,
hormone replacement therapy (HRT), and anthropometric measures. Lifestyle
information (such as smoking, alcohol intake, and physical activity) and data
on coffee consumption one year before the interview (specified in cups per week
[one cup equivalent to 1.5 dL]) were also collected.
ER
and progesterone receptor (PR) content of breast tumors was routinely measured
in Sweden at the time of the study but not for tumors ≤1 cm in size. Therefore,
the quantitative receptor content (both ER and PR) was available for only 65.4%
(1,835 women) of the tumors.
For
the MARIE study, information on potential risk factors for breast cancer was
obtained in a face-to-face interview using a standardized questionnaire. The
consumption of caffeine-containing coffee was calculated in cups per day and
frequency. The analysis included only those women who answered both questions
on portion size and frequency of coffee consumption. The final study group
included 5,395 controls and 2,651 cases. Information on the ER and PR status of
tumors was obtained from medical records.
The
authors estimated odds ratios and corresponding 95% confidence intervals (CIs)
by using the multivariate logistic regression models fitted to examine breast
cancer risk in a stratified case-control analysis. Heterogeneity among ER
subtypes was evaluated in a case-only analysis, treating ER status as a
dependent variable and including coffee consumption as a covariate.
The
authors report that in both studies, the age at menarche was weakly but
positively associated with breast cancer (P=0.057 in the Swedish samples and
P=0.0026 in the MARIE samples). Family history of breast cancer, age at
menopause, parity, age of first birth, recent body mass index, use of HRT,
alcohol consumption, physical activity, and highest education level attained
were strongly significant for breast cancer risk.
The
variables found to be significantly associated with coffee consumption among
controls in the Swedish study were HRT (P=0.008), smoking (P<0.0001), and
highest education level attained (P=0.041).
In
the Swedish study, coffee consumption was associated with a modest decrease in
overall breast cancer risk in the age-adjusted model. The authors' main finding
was that the breast cancer risk reduction associated with higher coffee
consumption was significantly higher for ER-negative compared with ER-positive
tumors (P heterogeneity [age-adjusted]=0.004). This effect was independent of
HRT, smoking, highest education level attained, and average daily alcohol
consumption.
In
the multivariate-adjusted Swedish study, women who drank more than five cups of
coffee per day were 57% (P=0.0003) and 33% (P=0.034) less likely to get the
ER-negative and PR-negative disease, respectively, than the reference group.
The
authors attempted to validate the trend test results of the Swedish ER-negative
breast cancer subgroup by examining the results of the MARIE study. Though not
reaching statistical significance, the strongest protective effect from heavy
coffee consumption was similarly observed for the ER-negative subtype.
The
authors believe that, collectively, "the results from the two studies in
this paper support a protective effect of high intakes of coffee against
ER-negative breast cancer. The weaker associations found in the MARIE study may
perhaps be attributed to other factors related to coffee drinking, such as
brewing method, bean type, and caffeine content."
The
authors cite several other studies that examined the relationship between
direct measurements of coffee consumption or related variables and risk for
ER-positive and ER-negative breast cancers. While not finding any evidence that
coffee consumption increases the overall risk for postmenopausal breast cancer,
a high daily intake of coffee was associated with a significant decrease in
ER-negative breast cancer among postmenopausal women. "Future studies are
needed to confirm the effects of coffee consumption in the light of breast
cancer subtypes."
―Shari
Henson
References
1Magnusson C, Baron J,
Persson I, et al. Body size in different periods of life and breast cancer risk
in post-menopausal women. Int J Cancer. 1998;76(1):29-34.
2Flesch-Janys
D, Slanger T, Mutschelknauss E, et al. Risk
of different histological types of postmenopausal breast cancer by type and
regimen of menopausal hormone therapy. Int
J Cancer. 2008;123(4):933-941.
|